Given that leptin receptor antagonists effectively inhibit breast cancer in mouse models [49], it is promising that utilizing a synthetic analog or monoclonal antibody as a leptin receptor antagonist may become a new strategy for the treatment for pancreatic cancer. This evidence concerns the gene LEPR and breast carcinoma.